Tiamulin (Denagard[®]) by injection – PK/PD relationships with *M. hyorhinis* and *M. hyopneumoniae*

¹M. Makhanon, ²D.G.S. Burch, ³U. Klein

¹Novartis (Thailand) Ltd, Bangkok, Thailand: ²Octagon Services Ltd, Old Windsor, Berks, UK; ³Novartis Animal Health Inc, Basel, Switzerland

Introduction

Tiamulin by injection (Denagard[®] - Novartis AH Inc.) was shown to be particularly effective against *Mycoplasma hyorhinis* (*MHR*) associated arthritis in young growing swine, causing a marked reduction in swollen joints (1). An in-vitro microbiological study (2) showed that the minimum inhibitory concentrations (MICs) of tiamulin against both *MHR* and *M. hyopneumoniae* (*MHP*) were very low.

It was the purpose of this paper to look at the pharmacokinetic (PK) and pharmacodynamic (PD) relationships of tiamulin against mycoplasmal isolates from Thailand.

Materials and methods

Pharmacodynamics: The MIC 50 and MIC 90 values for tiamulin against 20 recent Thai isolates of *MH*P and *MHR* were reported (2).

 Table 1. Susceptibility of 20 recent Thai MHP and

 MHR isolates to tiamulin

Species	MIC 50	MIC 90	MIC range
	(µg/ml)	(µg/ml)	(µg/ml)
MHP	0.048	0.097	0.048-0.19
MHR	0.097	0.097	0.048-0.097

Pharmacokinetics: Tiamulin distributes well into joint fluid after intramuscular administration. The concentrations achieved in plasma and joint fluid following an injection of Denagard 20% at 15mg/kg bodyweight was described (3, 4 & 5). Peak concentrations (Cmax) of tiamulin in plasma were recorded as 0.61μ g/ml (4) and that, on average, concentrations in joint fluid were approximately 40% of plasma concentration (3 & 5) (Ref Figure 1).

Results and discussion

The correlation between plasma and joint fluid concentrations with the MIC 90 of MHP and MHR at 0.097μ g/ml are highlighted in Figure 1.

0.7 0.6 Tiamulin conc (µg/ml) 0.5 0.4 0.3 0.2 0.1 0 0 8 12 16 20 24 Plasma -Joint fluid MIC90

Fig 1. Correlation of tiamulin PK in plasma and joint

fluid and PD (MIC 90) against MHP and MHR

There is a good PK correlation with tiamulin concentrations in plasma exceeding the tiamulin MIC 90 for *MHP* over a 24 hour period. The recommended treatment interval is 3 applications over 3 consecutive days. Tiamulin concentrations in joint fluid are somewhat lower, but appear to cover 21 hours of the 24 hour (87.5%) dosing period at the MIC 90 concentration. Many bacteriostatic antibiotics, which exert a concentration-related effect on the ribosome and thereby inhibit protein production, demonstrate a post-antibiotic effect (PAE) inhibiting bacterial regrowth for several hours (6) after plasma or tissue concentrations decline. This is likely to be the case for tiamulin against *MHR*.

Denagard injection at 15mg/kg bwt correlates well with its indications for the treatment of both mycoplasmal pneumonia and arthritis.

References

1.Talummuk et al (2010) Proc. IPVS Congress, 2, 1012.

2. Thongkamkoon et al (2010) Proc. IPVS Congress, 2, 638.

3.McKellar et al (1993) Leo Report

4.McKellar et al (2004) Proc. IPVS Congress, 2, 622.

5.Skov & Nielsen (1988) Leo Reports

6. Diarra et al (1999) Int. J. of Antimicrob. Agents, 12, 229-237



